Neoadjuvant chemotherapy prior to radical cystectomy is not associated with an increased risk for major complications vs radical cystectomy alone, but it does increase the risk for bleeding requiring transfusion and sepsis.
Among men with intermediate- and high-risk disease, Black men had significant 22% and 37% lower odds of receiving definitive treatment, respectively, compared with White men, a study found.
Investigators reported 90- and 450-day complete response rates of 53% and 28%, respectively, according to interim results from a phase 2 trial.
There is an unmet need for systemic treatment options in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based neoadjuvant chemotherapy, according to investigators.
Receipt of neoadjuvant vs adjuvant chemotherapy did not differ significantly by clinical nodal stage.
Acute kidney injury frequently occurs during neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.
Management of metastatic renal cell carcinoma should be highly individualized, according to investigators.
In the VHA system, use of doublet therapy increased to more than 50% of mHSPC cases since 2020.
New study corroborates findings from a prior study of men receiving care in the Veterans Health Administration system.
As far as investigators are aware, their study is the first randomized controlled trial comparing radical prostatectomy and stereotactic body radiation therapy.
Please login or register first to view this content.
